Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

Shares of BTX opened at $0.84 on Thursday. The firm has a market capitalization of $49.12 million, a PE ratio of -0.42 and a beta of 4.61. The company’s 50-day moving average is $1.19 and its 200-day moving average is $1.63. Brooklyn ImmunoTherapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.